Royalty Pharma PLC (RPRX): Price and Financial Metrics

Royalty Pharma PLC (RPRX): $26.65

0.12 (-0.45%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add RPRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#38 of 339

in industry

RPRX Price/Volume Stats

Current price $26.65 52-week high $31.66
Prev. close $26.77 52-week low $25.20
Day low $26.58 Volume 1,857,600
Day high $26.87 Avg. volume 2,704,342
50-day MA $27.05 Dividend yield 3.14%
200-day MA $28.09 Market Cap 15.92B

RPRX Stock Price Chart Interactive Chart >


Royalty Pharma PLC (RPRX) Company Bio


Royalty Pharma ist ein US-amerikanisches Finanzunternehmen mit Sitz in New York City. Es besitzt Rechte an verschiedenen Medikamenten, welche von diversen Pharmariesen wie SanofiMerck & Co. oder Novartis vermarktet werden und kassiert dafür Anteile am Vertriebsumsatz (Royalty Interest). (Source:Wikipedia)


RPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

RPRX Latest Social Stream


Loading social stream, please wait...

View Full RPRX Social Stream

Latest RPRX News From Around the Web

Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the la

Yahoo | November 27, 2023

Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%

Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...

Yahoo | November 26, 2023

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophreniaPhase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accele

Yahoo | November 13, 2023

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

TEL AVIV, Israel & NEW YORK, November 13, 2023--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypica

Yahoo | November 13, 2023

The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis

Decoding Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

Yahoo | November 9, 2023

Read More 'RPRX' Stories Here

RPRX Price Returns

1-mo -1.00%
3-mo -2.22%
6-mo -4.54%
1-year -10.74%
3-year -29.74%
5-year N/A
YTD -3.72%
2023 -27.08%
2022 0.99%
2021 -19.09%
2020 N/A
2019 N/A

RPRX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RPRX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!